Mutational signatures: emerging concepts, caveats and clinical applications
Whole-genome sequencing has brought the cancer genomics community into new territory.
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Thanks to the sheer power provided by the thousands of mutations present in each patient's …
Genomic and phenotypic heterogeneity in prostate cancer
From a clinical, morphological and molecular perspective, prostate cancer is a
heterogeneous disease. Primary prostate cancers are often multifocal, having …
heterogeneous disease. Primary prostate cancers are often multifocal, having …
[HTML][HTML] The genecards suite
The GeneCards® database of human genes was launched in 1997 and has expanded
since then to encompass gene-centric, disease-centric, and pathway-centric entities and …
since then to encompass gene-centric, disease-centric, and pathway-centric entities and …
[HTML][HTML] Biologically informed deep neural network for prostate cancer discovery
The determination of molecular features that mediate clinically aggressive phenotypes in
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
prostate cancer remains a major biological and clinical challenge,. Recent advances in …
[HTML][HTML] Inter-and intra-tumor heterogeneity of metastatic prostate cancer determined by digital spatial gene expression profiling
Metastatic prostate cancer (mPC) comprises a spectrum of diverse phenotypes. However,
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …
the extent of inter-and intra-tumor heterogeneity is not established. Here we use digital …
Biomarkers associating with PARP inhibitor benefit in prostate cancer in the TOPARP-B trial
PARP inhibitors are approved for treating advanced prostate cancers (APC) with various
defective DNA repair genes; however, further studies to clinically qualify predictive …
defective DNA repair genes; however, further studies to clinically qualify predictive …
[HTML][HTML] Hereditary prostate cancer: genes related, target therapy and prevention
MT Vietri, G D'Elia, G Caliendo, M Resse… - International journal of …, 2021 - mdpi.com
Prostate cancer (PCa) is globally the second most diagnosed cancer type and the most
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …
common cause of cancer-related deaths in men. Family history of PCa, hereditary breast …
Genomic features and classification of homologous recombination deficient pancreatic ductal adenocarcinoma
T Golan, GM O'Kane, RE Denroche… - Gastroenterology, 2021 - Elsevier
Background and Aims Homologous recombination deficiency (HRD) in pancreatic ductal
adenocarcinoma (PDAC), remains poorly defined beyond germline (g) alterations in …
adenocarcinoma (PDAC), remains poorly defined beyond germline (g) alterations in …
Pioneer of prostate cancer: past, present and the future of FOXA1
Prostate cancer is the most commonly diagnosed non-cutaneous cancers in North American
men. While androgen deprivation has remained as the cornerstone of prostate cancer …
men. While androgen deprivation has remained as the cornerstone of prostate cancer …
Homologous recombination deficiency (HRD) score in germline BRCA2- versus ATM-altered prostate cancer
The homologous recombination deficiency (HRD) score integrates three DNA-based
measures of genomic instability, and has been understudied in prostate cancer. Given the …
measures of genomic instability, and has been understudied in prostate cancer. Given the …